{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:04:38Z","timestamp":1761948278480,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.vhri.2017.03.005","type":"journal-article","created":{"date-parts":[[2017,5,17]],"date-time":"2017-05-17T03:15:21Z","timestamp":1494990921000},"page":"28-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Estudio de impacto presupuestal de Daclatasvir asociado a Asunaprevir desde la perspectiva del sistema de salud p\u00fablico chileno"],"prefix":"10.1016","volume":"14","author":[{"given":"C.","family":"Vargas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Espinoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Giglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Soza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vhri.2017.03.005_bib1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.vhri.2017.03.005_bib2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","article-title":"The global burden of hepatitis C","volume":"1","author":"Lavanchy","year":"2009","journal-title":"Liver Int"},{"journal-title":"Hepatitis C","year":"2014","key":"10.1016\/j.vhri.2017.03.005_bib3"},{"journal-title":"Guidelines for the screening, care and treatment of persons with hepatitis C infection","year":"2014","key":"10.1016\/j.vhri.2017.03.005_bib4"},{"key":"10.1016\/j.vhri.2017.03.005_bib5","first-page":"274","article-title":"Resultados virol\u00f3gicos finales del plan piloto de tratamiento de la hepatitis C","volume":"19","author":"Soza","year":"2008","journal-title":"Gastr Latinoam"},{"key":"10.1016\/j.vhri.2017.03.005_bib6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL Recommendations on Treatment of Hepatitis C 2015","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.vhri.2017.03.005_bib7","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.vhri.2017.03.005_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141660","article-title":"Cost Effectiveness of Daclatasvir\/Asunaprevir Versus Peginterferon\/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naive Patients in Chile","volume":"10","author":"Vargas","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.vhri.2017.03.005_bib9","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1524-4733.2007.00187.x","article-title":"Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis","volume":"10","author":"Mauskopf","year":"2007","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2017.03.005_bib10","series-title":"HEPATITIS C (CIE 10: B17.1; B18.2): SITUACI\u00d3N EPIDEMIOL\u00d3GICA, ENERO-JUNIO, 2014","first-page":"1","author":"MINSAL","year":"2014"},{"key":"10.1016\/j.vhri.2017.03.005_bib12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1665-2681(19)32076-9","article-title":"Incidence and prevalence of hepatitis C virus infection in Chile","volume":"4","author":"Gonzalez","year":"2005","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.vhri.2017.03.005_bib13","first-page":"615","article-title":"Prevalence of antibody to hepatitis C virus in blood donors. Analysis of confirmed results","volume":"124","author":"C","year":"1996","journal-title":"Rev Med Chil"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221210991730016X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221210991730016X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:09:59Z","timestamp":1761941399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221210991730016X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":12,"alternative-id":["S221210991730016X"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2017.03.005","relation":{},"ISSN":["2212-1099"],"issn-type":[{"type":"print","value":"2212-1099"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estudio de impacto presupuestal de Daclatasvir asociado a Asunaprevir desde la perspectiva del sistema de salud p\u00fablico chileno","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2017.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research (ISPOR).","name":"copyright","label":"Copyright"}]}}